Mr. Hobbs is an entrepreneurial senior executive with over 40 years of demonstrated success in profitable medical device and combination drug/device product business creation and growth, general management, sales and marketing, and product development. He is a renowned expert in combination drug/device technologies, having developed and commercialized numerous combination products throughout this career. In addition to Syncromune, he is also a Visiting Scholar and Entrepreneur in Residence for the Translational Accelerator at Brigham and Women’s Hospital, Harvard Medical School. Formerly he was President and CEO of Antares Pharma, Inc. (NASDAQ: ATRS), a specialty pharmaceutical and drug/device combination company. Prior to ATRS, he was President and CEO of Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company developing a novel drug/device combination cancer therapy. Prior to Delcath Systems, Inc., Mr. Hobbs served as Co-Founder, President and CEO of AngioDynamics, Inc. (NASDAQ: ANGO). He grew the company into a leading medical technology and oncology company which he took public in 2004. ANGO was the best performing medical technology IPO of the class of 2004, also earning the top honors in 2005 and 2006. It was also recognized in Business Week as a “Hot 100 Top Growth Company” for 2005 and 2006 and received a #11 ranking in Forbes “Best 200 Small Companies” in 2006. Prior to starting AngioDynamics, Mr. Hobbs was Director of Marketing and Product Development at NAMIC, Founder, President and CEO of Hobbs Medical, Inc., and a Product Development Engineer at Cook Incorporated. He is a highly sought-after board director and has served on numerous public and private company boards throughout his career, including at present 3 other companies in addition to Syncromune. Mr. Hobbs received a B.S. degree in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts (Lowell).